14 results on '"Dickenson, Ruth E."'
Search Results
2. EGR1 regulates oral epithelial cell responses toCandida albicansvia the EGFR- ERK1/2 pathway
- Author
-
Dickenson, Ruth E., primary, Pellon, Aize, additional, Ponde, Nicole O., additional, Hepworth, Olivia, additional, Daniels Gatward, Lydia F., additional, Naglik, Julian R., additional, and Moyes, David L., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Functions of IFNλs in Anti-Bacterial Immunity at Mucosal Barriers
- Author
-
Alphonse, Noémie, Dickenson, Ruth E, Alrehaili, Abrar, and Odendall, Charlotte
- Subjects
Model organisms ,Human Biology & Physiology ,Bacteria ,Virus Diseases ,FOS: Clinical medicine ,Immunology ,Cytokines ,Humans ,Immunology and Allergy ,Infectious Disease ,Intestinal Mucosa ,Antiviral Agents - Abstract
Type III interferons (IFNs), or IFNλs, are cytokines produced in response to microbial ligands. They signal through the IFNλ receptor complex (IFNLR), which is located on epithelial cells and select immune cells at barrier sites. As well as being induced during bacterial or viral infection, type III IFNs are produced in response to the microbiota in the lung and intestinal epithelium where they cultivate a resting antiviral state. While the multiple anti-viral activities of IFNλs have been extensively studied, their roles in immunity against bacteria are only recently emerging. Type III IFNs increase epithelial barrier integrity and protect from infection in the intestine but were shown to increase susceptibility to bacterial superinfections in the respiratory tract. Therefore, the effects of IFNλ can be beneficial or detrimental to the host during bacterial infections, depending on timing and biological contexts. This duality will affect the potential benefits of IFNλs as therapeutic agents. In this review, we summarize the current knowledge on IFNλ induction and signaling, as well as their roles at different barrier sites in the context of anti-bacterial immunity.
- Published
- 2022
- Full Text
- View/download PDF
4. A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling
- Author
-
Alphonse, Noémie, primary, Wanford, Joseph J., additional, Voak, Andrew A., additional, Gay, Jack, additional, Venkhaya, Shayla, additional, Burroughs, Owen, additional, Mathew, Sanjana, additional, Lee, Truelian, additional, Evans, Sasha L., additional, Zhao, Weiting, additional, Frowde, Kyle, additional, Alrehaili, Abrar, additional, Dickenson, Ruth E., additional, Munk, Mads, additional, Panina, Svetlana, additional, Mahmood, Ishraque F., additional, Llorian, Miriam, additional, Stanifer, Megan L., additional, Boulant, Steeve, additional, Berchtold, Martin W., additional, Bergeron, Julien R.C., additional, Wack, Andreas, additional, Lesser, Cammie F., additional, and Odendall, Charlotte, additional
- Published
- 2022
- Full Text
- View/download PDF
5. A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling
- Author
-
Alphonse, Noémie, Wanford, Joseph J., Voak, Andrew A., Gay, Jack, Venkhaya, Shayla, Burroughs, Owen, Mathew, Sanjana, Lee, Truelian, Evans, Sasha L., Zhao, Weiting, Frowde, Kyle, Alrehaili, Abrar, Dickenson, Ruth E., Munk, Mads, Panina, Svetlana, Mahmood, Ishraque F., Llorian, Miriam, Stanifer, Megan L., Boulant, Steeve, Berchtold, Martin W., Bergeron, Julien R. C., Wack, Andreas, Lesser, Cammie F., Odendall, Charlotte, Alphonse, Noémie, Wanford, Joseph J., Voak, Andrew A., Gay, Jack, Venkhaya, Shayla, Burroughs, Owen, Mathew, Sanjana, Lee, Truelian, Evans, Sasha L., Zhao, Weiting, Frowde, Kyle, Alrehaili, Abrar, Dickenson, Ruth E., Munk, Mads, Panina, Svetlana, Mahmood, Ishraque F., Llorian, Miriam, Stanifer, Megan L., Boulant, Steeve, Berchtold, Martin W., Bergeron, Julien R. C., Wack, Andreas, Lesser, Cammie F., and Odendall, Charlotte
- Abstract
Interferons (IFNs) induce an antimicrobial state, protecting tissues from infection. Many viruses inhibit IFN signaling, but whether bacterial pathogens evade IFN responses remains unclear. Here, we demonstrate that the Shigella OspC family of type-III-secreted effectors blocks IFN signaling independently of its cell death inhibitory activity. Rather, IFN inhibition was mediated by the binding of OspC1 and OspC3 to the Ca2+ sensor calmodulin (CaM), blocking CaM kinase II and downstream JAK/STAT signaling. The growth of Shigella lacking OspC1 and OspC3 was attenuated in epithelial cells and in a murine model of infection. This phenotype was rescued in both models by the depletion of IFN receptors. OspC homologs conserved in additional pathogens not only bound CaM but also inhibited IFN, suggesting a widespread virulence strategy. These findings reveal a conserved but previously undescribed molecular mechanism of IFN inhibition and demonstrate the critical role of Ca2+ and IFN targeting in bacterial pathogenesis.
- Published
- 2022
6. Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation
- Author
-
Lista, Maria Jose, primary, Matos, Pedro M., additional, Maguire, Thomas J. A., additional, Poulton, Kate, additional, Ortiz-Zapater, Elena, additional, Page, Robert, additional, Sertkaya, Helin, additional, Ortega-Prieto, Ana M., additional, Scourfield, Edward, additional, O’Byrne, Aoife M., additional, Bouton, Clement, additional, Dickenson, Ruth E., additional, Ficarelli, Mattia, additional, Jimenez-Guardeño, Jose M., additional, Howard, Mark, additional, Betancor, Gilberto, additional, Galao, Rui Pedro, additional, Pickering, Suzanne, additional, Signell, Adrian W., additional, Wilson, Harry, additional, Cliff, Penelope, additional, Kia Ik, Mark Tan, additional, Patel, Amita, additional, MacMahon, Eithne, additional, Cunningham, Emma, additional, Doores, Katie, additional, Agromayor, Monica, additional, Martin-Serrano, Juan, additional, Perucha, Esperanza, additional, Mischo, Hannah E., additional, Shankar-Hari, Manu, additional, Batra, Rahul, additional, Edgeworth, Jonathan, additional, Zuckerman, Mark, additional, Malim, Michael H., additional, Neil, Stuart, additional, and Martinez-Nunez, Rocio Teresa, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections
- Author
-
Dupont, Liane, primary, Snell, Luke B., additional, Graham, Carl, additional, Seow, Jeffrey, additional, Merrick, Blair, additional, Lechmere, Thomas, additional, Hallett, Sadie R., additional, Charalampous, Themoula, additional, Alcolea-Medina, Adela, additional, Huettner, Isabella, additional, Maguire, Thomas J. A., additional, Acors, Sam, additional, Almeida, Nathalia, additional, Cox, Daniel, additional, Dickenson, Ruth E., additional, Galao, Rui Pedro, additional, Jimenez-Guardeño, Jose M., additional, Kouphou, Neophytos, additional, Lista, Marie Jose, additional, Pickering, Suzanne, additional, Ortega-Prieto, Ana Maria, additional, Wilson, Harry, additional, Winstone, Helena, additional, Fairhead, Cassandra, additional, Su, Jia, additional, Nebbia, Gaia, additional, Batra, Rahul, additional, Neil, Stuart, additional, Shankar-Hari, Manu, additional, Edgeworth, Jonathan D., additional, Malim, Michael H., additional, and Doores, Katie J., additional
- Published
- 2021
- Full Text
- View/download PDF
8. Interferons: Tug of War Between Bacteria and Their Host
- Author
-
Alphonse, Noémie, primary, Dickenson, Ruth E., additional, and Odendall, Charlotte, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
- Author
-
Wells, Philippa M., primary, Doores, Katie J., additional, Couvreur, Simon, additional, Nunez, Rocio Martinez, additional, Seow, Jeffrey, additional, Graham, Carl, additional, Acors, Sam, additional, Kouphou, Neophytos, additional, Neil, Stuart J.D., additional, Tedder, Richard S., additional, Matos, Pedro M., additional, Poulton, Kate, additional, Lista, Maria Jose, additional, Dickenson, Ruth E., additional, Sertkaya, Helin, additional, Maguire, Thomas J.A., additional, Scourfield, Edward J., additional, Bowyer, Ruth C.E., additional, Hart, Deborah, additional, O'Byrne, Aoife, additional, Steel, Kathryn J.A., additional, Hemmings, Oliver, additional, Rosadas, Carolina, additional, McClure, Myra O., additional, Capedevilla-pujol, Joan, additional, Wolf, Jonathan, additional, Ourselin, Sebastien, additional, Brown, Matthew A., additional, Malim, Michael H., additional, Spector, Tim, additional, and Steves, Claire J., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation
- Author
-
Lista, Maria Jose, primary, Matos, Pedro M., additional, Maguire, Thomas J. A., additional, Poulton, Kate, additional, Ortiz-Zapater, Elena, additional, Page, Robert, additional, Sertkaya, Helin, additional, Ortega-Prieto, Ana M., additional, O’Byrne, Aoife M., additional, Bouton, Clement, additional, Dickenson, Ruth E, additional, Ficarelli, Mattia, additional, Jimenez-Guardeño, Jose M., additional, Howard, Mark, additional, Betancor, Gilberto, additional, Galao, Rui Pedro, additional, Pickering, Suzanne, additional, Signell, Adrian W, additional, Wilson, Harry, additional, Cliff, Penelope, additional, Tan Kia Ik, Mark, additional, Patel, Amita, additional, MacMahon, Eithne, additional, Cunningham, Emma, additional, Doores, Katie, additional, Agromayor, Monica, additional, Martin-Serrano, Juan, additional, Perucha, Esperanza, additional, Mischo, Hannah E., additional, Shankar-Hari, Manu, additional, Batra, Rahul, additional, Edgeworth, Jonathan, additional, Zuckerman, Mark, additional, Malim, Michael H., additional, Neil, Stuart, additional, and Martinez-Nunez, Rocio Teresa, additional
- Published
- 2020
- Full Text
- View/download PDF
11. COVID-19 and emerging viral infections: The case for interferon lambda
- Author
-
Prokunina-Olsson, Ludmila, primary, Alphonse, Noémie, additional, Dickenson, Ruth E., additional, Durbin, Joan E., additional, Glenn, Jeffrey S., additional, Hartmann, Rune, additional, Kotenko, Sergei V., additional, Lazear, Helen M., additional, O’Brien, Thomas R., additional, Odendall, Charlotte, additional, Onabajo, Olusegun O., additional, Piontkivska, Helen, additional, Santer, Deanna M., additional, Reich, Nancy C., additional, Wack, Andreas, additional, and Zanoni, Ivan, additional
- Published
- 2020
- Full Text
- View/download PDF
12. EGR1 regulates oral epithelial cell responses to Candida albicans via the EGFR- ERK1/2 pathway.
- Author
-
Dickenson RE, Pellon A, Ponde NO, Hepworth O, Daniels Gatward LF, Naglik JR, and Moyes DL
- Abstract
Candida albicans is a fungal pathobiont colonising mucosal surfaces of the human body, including the oral cavity. Under certain predisposing conditions, C. albicans invades mucosal tissues activating EGFR-MAPK signalling pathways in epithelial cells via the action of its peptide toxin candidalysin. However, our knowledge of the epithelial mechanisms involved during C. albicans colonisation is rudimentary. Here, we describe the role of the transcription factor early growth response protein 1 (EGR1) in human oral epithelial cells (OECs) in response to C. albicans . EGR1 expression increases in OECs when exposed to C. albicans independently of fungal viability, morphology, or candidalysin release, suggesting EGR1 is involved in the fundamental recognition of C. albicans, rather than in response to invasion or 'pathogenesis'. Upregulation of EGR1 is mediated by EGFR via Raf1, ERK1/2 and NF-κB signalling but not PI3K/mTOR signalling. Notably, EGR1 mRNA silencing impacts on anti- C. albicans immunity, reducing GM-CSF, IL-1α and IL-1β release, and increasing IL-6 and IL-8 production. These findings identify an important role for EGR1 in priming epithelial cells to respond to subsequent invasive infection by C. albicans and elucidate the regulation circuit of this transcription factor after contact.
- Published
- 2023
- Full Text
- View/download PDF
13. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
- Author
-
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Hallett SR, Charalampous T, Alcolea-Medina A, Huettner I, Maguire TJA, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Jimenez-Guardeño JM, Kouphou N, Lista MJ, Pickering S, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su J, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, and Doores KJ
- Abstract
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross-neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants.
- Published
- 2021
- Full Text
- View/download PDF
14. Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation.
- Author
-
Lista MJ, Matos PM, Maguire TJA, Poulton K, Ortiz-Zapater E, Page R, Sertkaya H, Ortega-Prieto AM, O'Byrne AM, Bouton C, Dickenson RE, Ficarelli M, Jimenez-Guardeño JM, Howard M, Betancor G, Galao RP, Pickering S, Signell AW, Wilson H, Cliff P, Ik MTK, Patel A, MacMahon E, Cunningham E, Doores K, Agromayor M, Martin-Serrano J, Perucha E, Mischo HE, Shankar-Hari M, Batra R, Edgeworth J, Zuckerman M, Malim MH, Neil S, and Martinez-Nunez RT
- Abstract
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for SARS-CoV-2 nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared One-step RT-qPCR reagents: TaqMan Fast Virus 1-Step Master Mix (FastVirus, ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna
® Universal Probe One-Step RT-qPCR Kit (Luna, NEB). We used primer-probes that detect viral N (EUA CDC) and RdRP (PHE guidelines). All RNA extraction methods provided similar results. FastVirus and Luna proved most sensitive. N detection was more reliable than that of RdRP, particularly in samples with low viral titres. Importantly, we demonstrate that treatment of nasopharyngeal swabs with 70 degrees for 10 or 30 min, or 90 degrees for 10 or 30 min (both original variant and B 1.1.7) inactivates SARS-CoV-2 employing plaque assays, and that it has minimal impact on the sensitivity of the qPCR in clinical samples. These findings make SARS-CoV-2 testing portable to settings that do not have CL-3 facilities. In summary, we provide several testing pipelines that can be easily implemented in other laboratories and have made all our protocols and SOPs freely available at https://osf.io/uebvj/ .- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.